A major clinical trial shows that ultrasound-guided carpal tunnel release delivers faster recovery and higher patient satisfaction than traditional approaches, with most people returning to work within four days. The findings come from the largest prospective study of this procedure ever conducted in the United States, offering new evidence that this minimally invasive technique could reshape how carpal tunnel syndrome is treated.

What Makes This Study Different from Previous Carpal Tunnel Research?

The MISSION registry (Post-Market RegIStry of the Patient Experience when uSing UltraGuIdeCTR fOr Carpal TuNnel Release) tracked real-world outcomes across 22 clinical sites in the United States, following 887 patients who underwent ultrasound-guided carpal tunnel release (UGCTR) using the UltraGuideCTR device. Researchers published their six-month findings in the Journal of Hand Surgery Global Online, comparing this minimally invasive approach to traditional open surgery and endoscopic methods.

What sets this research apart is its size and scope. Previous studies of carpal tunnel procedures typically involved smaller patient groups. This registry captured outcomes from over 1,000 hands treated across multiple centers, providing what researchers describe as a new benchmark for safety and effectiveness in carpal tunnel care. The study also examined something rarely studied before: the ability to treat both hands simultaneously in patients with bilateral carpal tunnel syndrome, a condition affecting roughly one in five patients with the disorder.

How Does Ultrasound-Guided Carpal Tunnel Release Work?

• Imaging Precision: Ultrasound guidance allows surgeons to visualize the carpal tunnel and surrounding structures in real time, enabling them to release the compressed nerve with minimal tissue disruption.
• Minimal Incision: The procedure requires only a small wrist incision averaging 5 millimeters, roughly the size of a pencil tip, compared to larger incisions needed for traditional open surgery.
• Local Anesthesia Option: About 82% of procedures were performed using only local anesthesia without a tourniquet, meaning patients remain awake and can go home the same day without general anesthesia risks.
• Suture-Free Closure: In 90% of cases, the tiny incision closed without requiring sutures, reducing wound care complexity and infection risk.

Carpal tunnel syndrome occurs when the median nerve, which runs through a narrow tunnel in the wrist, becomes compressed. This compression causes numbness, tingling, and weakness in the hand. Traditional open surgery requires a larger incision and longer recovery, while endoscopic approaches use a camera but still involve more tissue trauma than the ultrasound-guided method.

What Were the Key Recovery and Satisfaction Results?

The data paint a compelling picture of rapid functional recovery. Patients treated with UGCTR experienced significant improvement in symptoms, function, and pain that persisted through the six-month follow-up period. The median time to resume normal daily activities was just three days, and patients returned to work in a median of four days.

Patient satisfaction was notably high: 89.9% of all treated hands showed strong satisfaction with the procedure. This matters because carpal tunnel syndrome affects millions of working-age adults, and time away from employment creates financial hardship. Nearly two-thirds of the study participants were employed at the time of treatment, making rapid return to work a significant practical benefit.

Perhaps most striking, the study reported zero intraoperative complications and no serious adverse events across the entire cohort. This safety profile stands out in surgical research, where even minimally invasive procedures typically carry some risk of nerve injury, infection, or recurrence.

"This paper is significant because the results demonstrate real-world, patient-reported experiences across the largest set of CTS patients in a single study, establishing a new benchmark for safety, efficacy and patient outcomes in carpal tunnel release procedures," said Dr. Victor Marwin, an orthopedic hand surgeon with Bluegrass Orthopaedics in Lexington, Kentucky, and principal investigator for MISSION.

Dr. Victor Marwin, Orthopedic Hand Surgeon at Bluegrass Orthopaedics

Can This Procedure Treat Both Hands at Once?

One of the most clinically significant findings involves bilateral procedures. About 22% of study participants underwent simultaneous treatment of both hands during a single surgical session. This is important because bilateral carpal tunnel syndrome is common, and patients typically face two separate surgeries and two separate recovery periods with traditional approaches.

The MISSION registry found that clinical outcomes for simultaneous bilateral procedures were comparable to those for single-hand procedures, meaning patients could recover from both hands at once without compromising safety or effectiveness. This has major implications for healthcare efficiency and patient convenience.

What Do Healthcare Systems Stand to Gain?

Beyond individual patient benefits, the research highlights potential cost savings for healthcare systems. Carpal tunnel syndrome generates over $2 billion in annual healthcare costs in the United States, driven largely by lost work time, repeated medical visits, and surgical expenses. Procedures that enable rapid functional recovery without compromising safety could meaningfully reduce this burden.

The study also noted advantages over other carpal tunnel approaches: UGCTR showed higher use of local anesthesia only, smaller incisions, more suture-free closures, lower opioid use, less wound pain and sensitivity, and higher overall procedural and wound satisfaction compared to both open carpal tunnel release (OCTR) and endoscopic carpal tunnel release (ECTR).

"These findings reinforce Sonex Health's commitment to advancing ultrasound-guided solutions that improve safety, accelerate recovery and enhance the patient experience. This compelling real-world outcomes data also supports the use of UGCTR in routine clinical practice to simultaneously treat both hands of patients diagnosed with bilateral CTS, which is common in this patient population," said Bob Paulson, President and CEO of Sonex Health.

Bob Paulson, President and CEO of Sonex Health

The MISSION registry represents one of 18 peer-reviewed publications now documenting UGCTR outcomes across more than 1,400 patients and 2,000 hands. This growing body of evidence is being used to educate physicians, patients, and insurance companies about the benefits of the ultrasound-guided approach, potentially shifting treatment patterns toward this less invasive option.